Not every special purpose acquisition company (SPAC) deal in medtech is an instant success.
On 28 September LumiraDx, the London-based point-of-care diagnostics manufacturer, floated on the NASDAQ following its merger with the SPAC...
Analyst Insight: Justifying A Price Target Following Poor SPAC Reception
In a discussion with Medtech Insight, analysts at Ladenburg Thalmann argued the case for their LumiraDX $14.75 price target.
